Ignite Creation Date:
2024-05-06 @ 5:43 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05408845
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2022-06-02
Brief Title:
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment Chemotherapy With Docetaxel Plus Trastuzumab for Recurrent Metastatic or Unresectable HER2-Positive Salivary Gland Cancer
Sponsor:
NRG Oncology
Organization:
NRG Oncology
Organization Data
Organization:
NRG Oncology
Class:
OTHER
Study ID:
NRG-HN010
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
NRG Oncology
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |